HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements

Executive Summary

GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated
Advertisement

Related Content

Future Vaccine Growth Could Come From Recent Biotech Entrants – Tufts
Collaboration Deals With Pharma May Be Preferable To Licensing For Biotech
Big Pharma Gets Flexible As Licensing Activity Heats Up
Wyeth Manufacturing Capacity Serves As Lure For Biotech Deals, Essner Says
Merck RotaTeq Observational Study For Intussusception Will Enroll 28,000
Gardasil Goes To FDA; Merck Hopes For Mid-Year Approval Of HPV Vaccine
GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?
GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?
GSK Vaccine Portfolio Gets A Shot In The Arm From ID Biomedical Buy
GSK Recipe For R&D: Keep Drugs In Phase II Longer, Foster Accountability
Advertisement
UsernamePublicRestriction

Register

PS046758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel